Get started
Author

Celine Wilke

Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 · Fabrice André, Eva Ciruelos, et al. · New England Journal of Medicine · 2,598
PDF
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
2020 · Robert Zeiser, Nikolas von Bubnoff, et al. · New England Journal of Medicine · 881
PDF
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
2024 · Michael J Morris, Daniel Castellano, et al. · The Lancet · 346
PDF
A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors
2018 · Jordi Rodon, Giuseppe Curigliano, et al. · Oncotarget · 49
Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer
2016 · Michail Ignatiadis, Dimitrios Zardavas, et al. · PLoS ONE · 40
PDF
Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer
2024 · Kim N. Chi, Andrew J. Armstrong, et al. · European Urology · 36
Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial
2024 · Ken Herrmann, Andrei Gafita, et al. · EClinicalMedicine · 34
SOLAR-1: A phase III study of alpelisib + fulvestrant in men and postmenopausal women with HR+/HER2– advanced breast cancer (BC) progressing on or after prior aromatase inhibitor therapy.
2016 · Fabrice Andre, Mario Campone, et al. · Journal of Clinical Oncology · 15
Prognostic Value of Blood Biomarkers in Steroid-Refractory/Dependent Acute Graft-vs-Host Disease: A REACH2 Analysis
2023 · Gérard Socie, Dietger Niederwieser, et al. · Blood · 10
Preclinical studies on the use of a P-selectin-blocking monoclonal antibody to halt progression of myelofibrosis in the Gata1 mouse model
2022 · Paola Verachi, Francesca Gobbo, et al. · Experimental Hematology · 10
Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis
2020 · Andrew Charles Perkins, Kate Burbury, et al. · Blood · 10
Abstract CT061: A phase Ib study of alpelisib (BYL719) + everolimus ± exemestane in patients with advanced solid tumors or HR+/HER2-breast cancer
2016 · Jose Baselga, Giuseppe Curigliano, et al. · Cancer Research · 10
Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial
2025 · Mohamad Mohty, Gerard Socié, et al. · Journal of Clinical Oncology · 9
PDF
Tumor dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study.
2023 · Bernd J. Krause, Kim N. Chi, et al. · Journal of Clinical Oncology · 9
A phase 3 study of alpelisib (ALP) plus fulvestrant (FUL) in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) ABC progressing on or after aromatase inhibitor (AI) therapy: SOLAR-1.
2017 · Hope S. Rugo, Fabrice Andre, et al. · Journal of Clinical Oncology · 7
Imaging Efficacy of [18F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study
2025 · Andrei Iagaru, Jose F. Suarez, et al. · Journal of Nuclear Medicine · 4
PDF
Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results.
2023 · Ken Herrmann, Andrei Gafita, et al. · Journal of Clinical Oncology · 4
Patient-reported outcomes (PROs) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from SOLAR-1.
2019 · Ingrid A. Mayer, Hope S. Rugo, et al. · Journal of Clinical Oncology · 4
Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study
2020 · Gérard Socié, Dietger Niederwieser, et al. · Blood · 3
Preclinical Rationale for the Use of Crizanlizumab (SEG101) in Myelofibrosis
2020 · Paola Verachi, Fabrizio Martelli, et al. · Blood · 3
Imaging Efficacy of [18F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath—A Phase 3, Prospective Multicenter Study
2025 · Stefano Fanti, Javier Jesus Robles Barba, et al. · Journal of Nuclear Medicine · 2
PDF
Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results.
2024 · Ken Herrmann, Andrei Gafita, et al. · Journal of Clinical Oncology · 2
Alpelisib (ALP)+fulvestrant (FUL) in patients from Japan with advanced breast cancer: Subgroup analysis of SOLAR-1 trial
2019 · Hiroji Iwata, Toshinari Yamashita, et al. · Annals of Oncology · 2
Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial.
2019 · Dejan Juric, Sibylle Loibl, et al. · Journal of Clinical Oncology · 1
Feasibility study of cationic liposome-encapsulated paclitaxel in combination with paclitaxel followed by FEC as induction therapy in HER2-negative breast cancer.
2013 · Michail Ignatiadis, Marc Lemort, et al. · Journal of Clinical Oncology
Works count: 25
Citation count: 4,080
H-index: 10
I10-index: 12
Year
Topic
Type